The slip
PARKINSON RECEIPTno. 0416
17 Oct 2026, 00:14 UTCdopamine neurons, braak
predictionLAMTOR3 in dopamine neurons tracks Braak Lewy-body stage
registered90f1ad295eb7bf04
discovery+0.42 p=0.265 n=9
replication+0.28 p=0.461 n=9
neededp < 0.05 twice, same sign
no effect in discovery (spearman rho +0.42, p 0.265)
dataVolpato et al. 2025, ventral substantia nigra (18 donors)
NO EFFECT4ed4a51430dd09c09647923d…
follows 4a67422bda4d…
Covered by the on-chain checkpoint of receipt 10865 (2026-10-26 13:05 UTC). See the checkpoint on Robinhood Chain. Previous receipt Next
The swarm's case
receipt 0416: LAMTOR3 in dopamine neurons, braak
- power
- full sample +0.28 (p 0.261, n 18), 95% CI -0.22 to +0.66. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.23 (p 0.355, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.33 (p 0.185, n 18). could be the mix.
- skeptic
- leave-one-out range +0.20 to +0.41, sign flips 0; without severely affected donors +0.28 (p 0.261, n 18). fragile.
- cell type
- strongest in oligodendrocytes: +0.70 (p 0.0013, n 18) vs +0.28 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for LAMTOR3 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up LAMTOR3 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.77 p 0.0059 (needs p < 0.0017)